Over four months, people without structured support regained 10.75% of body weight. Tufts researcher Kelseanna Hollis-Hansen and Harvard's Dr Caroline Apovian weigh in.
Recap by typeshit. Full story at Newsweek.
A Future Health & Medical Innovation panel weighs how much of the growing interest in peptides and exosomes is backed by evidence.
The aging doctor shares a headline saying new studies point to GLP-1 drugs slowing the biological clock, and notes himself that more research is needed.
An explainer on how GLP-1 drugs act on reward and craving in the brain, and the research testing them against alcohol, nicotine and other substance use.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
Dr Kaydo notes the full phase 3 data was published September 29, 2026. Retatrutide is still investigational and not approved by the FDA.
Jay Goldberg of the Consumer Choice Center argues the $50 copay only covers some Medicare patients, and points to PBM reform and competition instead.
Loading…